Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioavailability of MK-1439 Experimental Nano Formulations in Healthy Adults (MK-1439-046)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02549040
Recruitment Status : Completed
First Posted : September 14, 2015
Results First Posted : February 22, 2019
Last Update Posted : February 22, 2019
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This study aims to evaluate and compare the relative bioavailability of different MK-1439 experimental nano formulations (NFs) with that of a MK-1439 film coated tablet.

Condition or disease Intervention/treatment Phase
Human Immunodeficiency Virus-1 (HIV-1) Drug: Treatment A: MK-1439 100 mg film coated tablet Drug: Treatment B: MK-1439 150 mg tablet (40% drug loaded granule) Drug: Treatment C: MK-1439 150 mg tablet (30% drug loaded granule) Drug: Treatment D: MK-1439 150 mg tablet (50% drug loaded granule) Drug: Treatment E: MK-1439 100 mg tablet (30% drug loaded granule) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Rapid Pharmacokinetic Trial of the Bioavailability of Four MK-1439 Nano Formulations in Healthy Adults
Actual Study Start Date : September 21, 2015
Actual Primary Completion Date : December 24, 2015
Actual Study Completion Date : December 24, 2015

Arm Intervention/treatment
Experimental: MK-1439 fixed sequence treatment
After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: MK-1439 100 mg film coated tablet. During Period 3, participants received Treatment C: MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.
Drug: Treatment A: MK-1439 100 mg film coated tablet
Single MK-1439 100 mg film coated tablet administered orally at the start of Period 2

Drug: Treatment B: MK-1439 150 mg tablet (40% drug loaded granule)
Single MK-1439 NF Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1

Drug: Treatment C: MK-1439 150 mg tablet (30% drug loaded granule)
Single MK-1439 NF Type 2 dose (150 mg tablet [30% drug loaded granule])administered orally at the start of Period 3

Drug: Treatment D: MK-1439 150 mg tablet (50% drug loaded granule)
Single MK-1439 NF Type 3 dose (150 mg tablet [50% drug loaded granule])administered orally at the start of Period 4

Drug: Treatment E: MK-1439 100 mg tablet (30% drug loaded granule)
Single MK-1439 NF Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5




Primary Outcome Measures :
  1. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439 [ Time Frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose ]
    During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-inf after a single administration of MK-1439.

  2. Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439 [ Time Frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose ]
    During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-last after a single administration of MK-1439.

  3. Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439 [ Time Frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose ]
    During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose to determine Cmax after a single administration of MK-1439.

  4. Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439 [ Time Frame: Periods 1 to 5: 24 hours post-dose ]
    During each of the 5 treatment periods, blood samples were collected 24 hours after dosing to determine C24hr after a single administration of MK-1439.

  5. Number of Participants Who Experienced at Least One Adverse Event [ Time Frame: Up to 16 days after last dose of study treatment (up to approximately 92 days) ]
    An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.

  6. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event [ Time Frame: Up to 4 days after last dose of study treatment (up to approximately 76 days) ]
    An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.


Secondary Outcome Measures :
  1. Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439 [ Time Frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours post-dose ]
    During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48 hours after dosing to determine AUC0-48hr after a single administration of MK-1439.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy participants
  • have been a non-smoker and/or have not used nicotine or nicotine-containing products for at least approximately 3 months

Exclusion Criteria:

  • is a pregnant or a nursing female
  • has a history of stroke, chronic seizures or major neurological disorder
  • has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
  • has a history of neoplastic disease (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02549040


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT02549040     History of Changes
Other Study ID Numbers: 1439-046
2015-002702-36 ( EudraCT Number )
MK-1439-046 ( Other Identifier: Merck Protocol Number )
First Posted: September 14, 2015    Key Record Dates
Results First Posted: February 22, 2019
Last Update Posted: February 22, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php

Additional relevant MeSH terms:
Layout table for MeSH terms
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases